The effect of thymosin α1 on mortality of critical COVID-19 patients: A multicenter retrospective study
Sun Q, Xie J, Zheng R, et al. International Immunopharmacology 2021;90:107143.
What it found
Before adjustment, 28-day mortality was lower in patients given thymosin alpha-1 (41.3% vs 60.6%). After propensity score matching for baseline differences (522 patients), it was 51.0% versus 52.9%, with no significant difference. A possible benefit in men was seen in one subgroup analysis.
Limitations
Retrospective records from 19 Chinese hospitals early in 2020. Treatment was not randomised, so unmeasured differences between groups may remain.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.